| Rochester Hills Oms, P.c. | |
|
1205 W University Dr Rochester Hills MI 48307-1864 | |
| (248) 651-4202 | |
| Not Available |
| Full Name | Rochester Hills Oms, P.c. |
|---|---|
| Speciality | Dentist |
| Location | 1205 W University Dr, Rochester Hills, Michigan |
| Authorized Official Name and Position | Lisa Marie Obry (OFFICE MANAGER) |
| Authorized Official Contact | 2486514202 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Rochester Hills Oms, P.c. 1205 W University Dr Rochester Hills MI 48307-1864 Ph: (248) 651-4202 | Rochester Hills Oms, P.c. 1205 W University Dr Rochester Hills MI 48307-1864 Ph: (248) 651-4202 |
| NPI Number | 1366745119 |
|---|---|
| Provider Enumeration Date | 12/17/2010 |
| Last Update Date | 11/02/2018 |
| Medicare PECOS PAC ID | 3173779527 |
|---|---|
| Medicare Enrollment ID | O20120820000025 |
News Archive
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning's ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.
An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366745119 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | (Michigan) | Primary |
| Provider Name | Aaron M Pokorny |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1366589228 PECOS PAC ID: 4688844491 Enrollment ID: I20110906000493 |
News Archive
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning's ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.
An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
› Verified 4 days ago
| Provider Name | Paul A Renke |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1114935632 PECOS PAC ID: 7416103866 Enrollment ID: I20120820000095 |
News Archive
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning's ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.
An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
› Verified 4 days ago
| Provider Name | Kathryn Ann Sonpal-tironi |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1417380387 PECOS PAC ID: 7315215894 Enrollment ID: I20170626001439 |
News Archive
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning's ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.
An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
› Verified 4 days ago
News Archive
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market—and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning's ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.
An over-the-counter (OTC) asthma inhaler up for approval by the U.S. Food & Drug Administration (FDA) endangers patients by encouraging substandard treatment, according to Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading nonprofit patient education and advocacy organization.
› Verified 4 days ago
Michigan Oral Rehabilitation And Periodontics Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1202 Walton Blvd, Suite 208, Rochester Hills, MI 48307 Phone: 248-703-2319 | |
David M Juliani Dds Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 441 S Livernois Rd, Suite 185, Rochester Hills, MI 48307 Phone: 248-651-2273 Fax: 248-651-2976 | |
Neil L Matthews Dds Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 305 Barclay Cir Ste 1004, Rochester Hills, MI 48307 Phone: 248-656-0680 Fax: 248-373-7672 | |
Great Lakes Sleep And Orofacial Pain Clinic Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 75 Barclay Cir Ste 205, Rochester Hills, MI 48307 Phone: 310-493-1133 | |
Dhillon Dental, Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 940 W Avon Rd Ste 12, Rochester Hills, MI 48307 Phone: 248-652-7172 | |
Thomas Chae Dds, Ms & Sophia Huynh, Dds, Ms Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 989 South Blvd E Ste 110, Rochester Hills, MI 48307 Phone: 248-243-8811 | |
Phyllis R Indianer Dds Plc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1423 Walton Blvd, Rochester Hills, MI 48309 Phone: 248-651-1555 Fax: 248-651-0560 |